Generated by AI
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapy candidates for cancer. The company uses its proprietary ADAPTIR and ADAPTIR-FLEX platforms to design mono-, bi-, and multi-specific antibody-based therapeutics intended to engage the immune system against tumor cells. Its current pipeline includes candidates for hematologic malignancies and solid tumors, with programs spanning clinical and preclinical development. Aptevo Therapeutics Inc. operates in the oncology and immuno-oncology segments of the healthcare market, where it contributes to the development of targeted biologic therapies for complex cancers. Headquartered in Seattle, Washington, the company concentrates on research-driven product development and collaboration-based innovation in modern cancer treatment.
Website2401 4th Avenue
Seattle, WA, 98121
United States
The latest articles about APVO.
Summary of Nov 18's posts. Generated by AI.
Summary of Mar 31's posts. Generated by AI.
Summary of Sep 18's posts. Generated by AI.
Summary of Sep 3's posts. Generated by AI.
Investors talking about APVO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.